000			01747 a2200493 4500
005			20250516102734.0
264		0	_c20121107
008			201211s 0 0 eng d
022			_a1872-7980
024	7		_a10.1016/j.canlet.2012.07.012 _2doi
040			_aNLM _beng _cNLM
100	1		_aAndersen, Brian M
245	0	0	_aIncreasing the efficacy of tumor cell vaccines by enhancing cross priming. _h[electronic resource]
260			_bCancer letters _cDec 2012
300			_a155-64 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAntigens, Neoplasm _ximmunology
650	0	4	_aApoptosis
650	0	4	_aAutophagy
650	0	4	_aBrain Neoplasms _ximmunology
650	0	4	_aCD8-Positive T-Lymphocytes _ximmunology
650	0	4	_aCancer Vaccines _xadministration & dosage
650	0	4	_aClinical Trials as Topic
650	0	4	_aCombined Modality Therapy
650	0	4	_aCross-Priming
650	0	4	_aDendritic Cells _ximmunology
650	0	4	_aDrug Design
650	0	4	_aGlioma _ximmunology
650	0	4	_aHumans
650	0	4	_aImmunization, Secondary
650	0	4	_aImmunologic Memory
650	0	4	_aImmunotherapy, Active
650	0	4	_aInterferon-alpha _xbiosynthesis
650	0	4	_aInterleukin-12 _xbiosynthesis
650	0	4	_aLigands
650	0	4	_aNeoplasms _xtherapy
650	0	4	_aReceptors, Immunologic _ximmunology
650	0	4	_aRemission Induction
650	0	4	_aToll-Like Receptors _ximmunology
650	0	4	_aTreatment Outcome
700	1		_aOhlfest, John R
773	0		_tCancer letters _gvol. 325 _gno. 2 _gp. 155-64
856	4	0	_uhttps://doi.org/10.1016/j.canlet.2012.07.012 _zAvailable from publisher's website
999			_c21956088 _d21956088